Indivior Pharmaceuticals Inc. (INDV) Options Positioning, Max Pain & Unusual Sweeps

INDV scores 51 out of 100, a letter grade of D, with the verdict "Roarable Sell — Underperform / Distribution Warning." The five pillar scores are: Fundamental Cash Engine 11/20 (ROIC 62.2%; FCF yield -2.24%); Whale/13F Flow 10/20 (institutional accumulation and options positioning); Insider Conviction 9/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit 7/20 (Beta 1.15; sector sensitivity); and Forensic Balance Sheet 14/20 (Altman Z 3.13; Piotroski F 5/9; Debt/Equity 0.85).

The pillar mix shows the rating's central tension. Returns on invested capital are reported as very high at 62.2%, yet the free cash flow yield is negative at -2.24%, so the reported profitability is not translating into cash available to shareholders on the RQD's measure. The balance-sheet pillar is the strongest component, supported by an Altman Z of 3.13 and a Piotroski F of 5/9, while insider and institutional pillars are weak. The macro pillar is the lowest, reflecting a beta of 1.15, which the rating treats as above-market sensitivity. For a prospective investor, the practical reading is that the score argues against treating the stock's earnings multiple alone as a sufficient reason to buy, and that the valuation case depends on whether cash generation catches up with reported earnings. This is an analytical framing of the source data, not personalized advice.

Indivior Pharmaceuticals Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Beyond sector and industry classification, the product, customer, and revenue-model details are —

Revenue rose from $1.09B in FY 2023 to $1.24B in FY 2025, and net income moved from -$126.0M to $210.0M over the same span. Per the market data, gross margin is 80.2%, operating margin 21.1%, and net margin 16.9%, with ROIC at 62.2%. The FY 2025 free cash flow of -$93.0M is consistent with the negative FCF yield of -2.24%. The Altman Z-Score is 3.13 and the Piotroski F-Score is 5/9. The Debt/Equity ratio is 0.85, and reported debt declined from $535.5M in FY 2023 to $290.0M in FY 2025, while cash was $195.0M at the latest reported period.

• 🐂 Primary Bull Case: Reported ROIC of 62.2% and FY 2025 net income of $210.0M, up from $7.0M in FY 2024, show earnings power that could support a re-rating if cash flow follows. With Fundamental Cash Engine at 11/20 (ROIC 62.2%, FCF yield -2.24%) and Institutional Whale Flow at 10/20, sustained execution supports upside toward the top of the $27.68 – $42.81 52-week range.
• 🐻 Primary Bear Case: Free cash flow was -$93.0M in FY 2025 and the FCF yield is -2.24%, so reported profits are not yet converting to cash for shareholders. Investors must weigh 19.8x trailing P/E and 13.4x EV/EBITDA against 21.1% operating margins and a 1.15 macro beta if sector demand softens.

— The Butterfly Supply-Chain Graph lists supply_chain as NONE with empty butterfly links and proprietary signals, so upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be identified from the provided sources.

• Key Question #1: What drives the gap between the 62.2% ROIC and the -2.24% FCF yield, and does FY 2025's -$93.0M free cash flow reflect working capital, capital expenditure, or one-time items?
• Key Question #2: What are the terms, timing, and financial implications of the proposed Supernus merger, and how would they affect the balance sheet and share count?
• Key Question #3: What share of revenue comes from SUBLOCADE versus other products, and how sustainable is the profitability growth the news feed describes?